Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tomhiro Mastuo"'
Autor:
Tomhiro Mastuo, Yasuyoshi Miyata, Tsutomu Yuno, Yuta Mukae, Asato Otsubo, Kensuke Mitsunari, Kojiro Ohba, Hideki Sakai
Publikováno v:
Molecules, Vol 25, Iss 3, p 575 (2020)
Bladder cancer (BC) is a representative of urological cancer with a high recurrence and metastasis potential. Currently, cisplatin-based chemotherapy and immune checkpoint inhibitors are used as standard therapy in patients with advanced/metastatic B
Externí odkaz:
https://doaj.org/article/7170fd330c5348b7b1abff3ac9244daa
Autor:
Yuta Mukai, Yasushi Mochizuki, Tsutomu Yuno, Tomhiro Mastuo, Hideki Sakai, Yasuyoshi Miyata, Asato Otsubo, Yuichiro Nakamura, Kojiro Ohba, Kensuke Mitsunari, Kyohei Araki
Publikováno v:
Molecular and Clinical Oncology
Molecular targeted therapies are commonly used in patients with metastatic renal cell carcinoma (RCC). However, the efficacy and safety of these therapeutic interventions require enhancement to improve prognosis in these patients. Royal jelly (RJ) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4044a31ebf786b497fbbe2969f335cb4
http://europepmc.org/articles/PMC7403815
http://europepmc.org/articles/PMC7403815
Autor:
Yasuyoshi Miyata, Tsutomu Yuno, Hideki Sakai, Kojiro Ohba, Kensuke Mitsunari, Yuta Mukae, Asato Otsubo, Tomhiro Mastuo
Publikováno v:
Molecules, Vol 25, Iss 3, p 575 (2020)
Molecules
Molecules
Bladder cancer (BC) is a representative of urological cancer with a high recurrence and metastasis potential. Currently, cisplatin-based chemotherapy and immune checkpoint inhibitors are used as standard therapy in patients with advanced/metastatic B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2288901ec5607e034b14b6728a4857b3
https://www.mdpi.com/1420-3049/25/3/575
https://www.mdpi.com/1420-3049/25/3/575
Autor:
Tomhiro Mastuo, Tsutomu Yuno, Yuta Mukai, Yasushi Mochizuki, Kojiro Ohba, Asato Otsubo, Hideki Sakai, Yasuyoshi Miyata, Yuichiro Nakamura, Kensuke Mitsunari, Kyohei Araki
Publikováno v:
Molecular and Clinical Oncology. 13:1-1
Molecular targeted therapies are commonly used in patients with metastatic renal cell carcinoma (RCC). However, the efficacy and safety of these therapeutic interventions require enhancement to improve prognosis in these patients. Royal jelly (RJ) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1074089196be3cca179dac2bd0f37c5
https://doi.org/10.3892/mco.2020.2148
https://doi.org/10.3892/mco.2020.2148